Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

274 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer.
Horeweg N, de Bruyn M, Nout RA, Stelloo E, Kedziersza K, León-Castillo A, Plat A, Mertz KD, Osse M, Jürgenliemk-Schulz IM, Lutgens LCHW, Jobsen JJ, van der Steen-Banasik EM, Smit VT, Creutzberg CL, Bosse T, Nijman HW, Koelzer VH, Church DN. Horeweg N, et al. Cancer Immunol Res. 2020 Dec;8(12):1508-1519. doi: 10.1158/2326-6066.CIR-20-0149. Epub 2020 Sep 30. Cancer Immunol Res. 2020. PMID: 32999003 Clinical Trial.
p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial.
Vermij L, Léon-Castillo A, Singh N, Powell ME, Edmondson RJ, Genestie C, Khaw P, Pyman J, McLachlin CM, Ghatage P, de Boer SM, Nijman HW, Smit VTHBM, Crosbie EJ, Leary A, Creutzberg CL, Horeweg N, Bosse T; TransPORTEC consortium. Vermij L, et al. Mod Pathol. 2022 Oct;35(10):1475-1483. doi: 10.1038/s41379-022-01102-x. Epub 2022 Jun 25. Mod Pathol. 2022. PMID: 35752743 Free PMC article. Clinical Trial.
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.
de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Kitchener HC, Nijman HW, Kruitwagen RF, Nout RA, Verhoeven-Adema KW, Smit VT, Putter H, Creutzberg CL; PORTEC study group. de Boer SM, et al. Lancet Oncol. 2016 Aug;17(8):1114-1126. doi: 10.1016/S1470-2045(16)30120-6. Epub 2016 Jul 7. Lancet Oncol. 2016. PMID: 27397040 Free article. Clinical Trial.
Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer.
de Boer SM, Wortman BG, Bosse T, Powell ME, Singh N, Hollema H, Wilson G, Chowdhury MN, Mileshkin L, Pyman J, Katsaros D, Carinelli S, Fyles A, McLachlin CM, Haie-Meder C, Duvillard P, Nout RA, Verhoeven-Adema KW, Putter H, Creutzberg CL, Smit VTHBM; for PORTEC Study Group. de Boer SM, et al. Among authors: smit vthbm. Ann Oncol. 2018 Feb 1;29(2):424-430. doi: 10.1093/annonc/mdx753. Ann Oncol. 2018. PMID: 29190319 Free PMC article. Clinical Trial.
274 results